Puma Biotechnology | PBYI - Stock


Puma Biotechnology reported $9.48M in Stock for its fiscal quarter ending in September of 2025.





Stock Change Date
Agios Pharmaceuticals USD 35.09M 2.17M Mar/2026
Alnylam Pharmaceuticals USD 200.15M 117.43M Mar/2026
Amgen USD 6.19B 39M Mar/2026
Biogen USD 1.95B 219.1M Mar/2026
BioMarin Pharmaceutical USD 1.27B 25.66M Mar/2026
Daiichi Sankyo JPY 608.55B 93.64B Sep/2025
Esperion Therapeutics USD 104.21M 915K Mar/2026
Exelixis USD 26.6M 4.92M Mar/2026
Gilead Sciences USD 1.91B 140M Mar/2026
Glaxosmithkline GBP 6.16B 39M Mar/2026
Incyte USD 115.62M 14.56M Mar/2026
MacroGenics USD 9.5M 1.59M Mar/2026
Moderna USD 146M 7M Mar/2026
Novartis USD 6.29B 17M Mar/2026
Pfizer USD 10.67B 13M Mar/2026
PTC Therapeutics USD 75.57M 4.08M Mar/2026
Puma Biotechnology USD 9.48M 885K Sep/2025
Regeneron Pharmaceuticals USD 3.1B 97.2M Mar/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sarepta Therapeutics USD 1B 86.37M Mar/2026
Takeda JPY 1.41T 107.71B Dec/2025
TG Therapeutics USD 129.03M 3.44M Mar/2026
Ultragenyx Pharmaceutical USD 55M 3M Mar/2026
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025
Vertex Pharmaceuticals USD 1.77B 79.9M Mar/2026